ERBB2 and non-small cell lung carcinoma: The randomized, blinded multicenter phase II trial DESTINY-Lung02 showed considerable and enduring antitumor responses of T-DXd in HER2-mutated NSCLC patients, with ORR of 49% and 56% at doses of 5.4 and 6.4 mg/kg, regardless of HER2 mutation type, amplification status, and prior treatment [39].